NCT07063901 Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
| NCT ID | NCT07063901 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central South University |
| Condition | Esophagus Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-06-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study aims to investigate a clinical cohort of patients with locally advanced esophageal cancer undergoing neoadjuvant chemoimmunotherapy. By integrating multimodal clinical data-including demographic characteristics, medical history, imaging studies, pathological findings, and laboratory tests-and employing deep learning algorithms, the study seeks to develop predictive models for the early and accurate assessment of treatment response prior to surgery. Specifically, this study focuses on addressing the following key scientific questions: 1. Can multimodal clinical data be used to construct an accurate model for predicting pathological complete response (pCR) following neoadjuvant therapy? 2. Can deep learning models enable early identification of patients with suboptimal response to neoadjuvant therapy, defined as stable disease (SD) or progressive disease (PD), before surgery?
Eligibility Criteria
Inclusion Criteria: 1. Patients with histologically confirmed esophageal cancer based on biopsy results; 2. Patients recommended for neoadjuvant chemoimmunotherapy following multidisciplinary team (MDT) discussion or evaluation by thoracic surgery specialists; 3. Patients who received neoadjuvant chemoimmunotherapy; 4. Patients with complete imaging data before and after neoadjuvant treatment. Exclusion Criteria: 1. Patients deemed eligible for surgery by the thoracic surgery team but who refused surgical treatment; 2. Patients with missing or poor-quality CT images; 3. Patients with concurrent malignancies other than esophageal cancer; 4. Patients with incomplete clinical data.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07063901 clinical trial?
This trial is open to participants of all sexes, studying Esophagus Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07063901 currently recruiting?
Yes, NCT07063901 is actively recruiting participants. Contact the research team at chenchen1981412@csu.edu.cn for enrollment information.
Where is the NCT07063901 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT07063901 clinical trial?
NCT07063901 is sponsored by Central South University. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.